ReviewMaterials today. Bio2025
Advancements in nanomedicine for modulating ischemic cardiomyopathy therapy.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immunothrombotic Cell-Cell Communication Networks in Coronary Atherosclerosis: Critical Insights from Single-Cell and Spatial Systems Biology.International journal of molecular sciences · 2026Review
- Programming the beating heart with polymer catalysis: a therapeutic microenvironment revolution.Journal of nanobiotechnology · 2026Review
- Nanozyme-Based Anti-Inflammatory Strategies in Cardiovascular Disease Management: Clinical Prospects and Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic cardiomyopathy receives significant attention due to its high mortality and morbidity worldwide. Numerous research has revealed that blood supply, ROS, inflammation, and thrombus play pivotal roles in the progression of myocardial damage and remodeling. The central approach for managing ischemic cardiomyopathy is the administration of therapeutic drugs against the pathological mechanism. Despite the development of abundant agents with therapeutic benefits, current therapeutic efficiency is insufficient for further clinical application due to its intrinsic limitations, including poor delivery efficiency and low retention capability. It is urged to seek alternative strategies to improve drug bioavailability and therapeutic index with high biocompatibility. With the emergence of nanotechnology, nanomedicine offer significant improvements to effectively deliver therapeutic molecules for treating ischemic cardiomyopathy. Recently, many biomaterials have been developed to enhance the efficiency of therapeutic drugs for the treatment of myocardial ischemic-related disease. This review summarizes the recent advances of nanomedicine in the treatment of ischemic cardiomyopathy, focusing on antithrombotic therapy, ROS-scavenging therapy, anti-inflammatory therapy, revascularization, and improving electrical conduction. We also discuss the potential limitations and further development of these therapeutic approaches to treat ischemic cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.